A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

According to the analyst, Syfovre presents a more attractive efficacy profile and a more advantageous label, permitting monthly or bi-monthly dosing and treatment beyond 12 months (although the ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

“The third quarter was marked by continued progress, including growth in SYFOVRE vial demand and the positive Phase 3 VALIANT study results in C3G and IC-MPGN. While SYFOVRE net sales fell short ...

Jefferies analysts have estimated Syfovre could make as much as $6 billion ... superstar status and the risks associated with its off-label use. In the age of AI, large data sets – like the ...

The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in commercial vial ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

Over the past few months, we have made meaningful progress towards our long-term goals, reaching key milestones such as generating continued growth in vial demand for SYFOVRE and presenting the ...